

Please add the attached initial paper copy of the "Sequence Listing" to the application.

In the Claims:

Please cancel claims 18 and 25 without prejudice.

Please amend claims 13-17, 19-22, 24, 26, ⁴³44, ⁴⁵46, and ^{50 54}51-55 as follows:

13. (AMENDED) [The use of Colostrinin in the manufacture of a]
A medicament comprising Colostrinin for use in the treatment of chronic disorders of the central nervous system.

B3
14. (AMENDED) The [use] medicament according to claim 13[,] for use in the treatment of neurological disorders and/or mental disorders.

sub F.7
15. (AMENDED) The [use] medicament according to claim 14[,] for use in the treatment of dementia and/or neurodegenerative diseases.

F
16. (AMENDED) The [use] medicament according to claim 14[,] for use in the treatment of [for use of] Alzheimer's disease and/or motor neurone disease.

B3

17. (AMENDED) The [use] medicament according to claim 14[,] for use in the treatment of psychosis and/or neurosis.

19. (AMENDED) [The use of Colostrinin in the manufacture of a] A medicament comprising Colostrinin for use in the treatment of chronic disorders of the immune system in humans.

B4

20. (TWICE AMENDED) The [use] medicament according to claim [18, or] 19 for use in the treatment of diseases with a bacterial [and] and/or viral aetiology, and/or for use in the treatment of acquired immunological deficiencies.

21. (TWICE AMENDED) The [use] medicament according to claim [18,] 19 for use in the treatment of bacterial and/or viral infections.

22. (TWICE AMENDED) The [use] medicament according to claim [18,] 19 wherein said Colostrinin is non-ovine Colostrinin.

B5

24. (AMENDED) A method of treating disorders of the central nervous system and/or of the immune system, comprising administering a

B5-
predetermined amount of a composition containing Colostrinin to a human
patient for a predetermined period of time.

~~B6~~ sub F37 ~~F~~
26. (TWICE AMENDED) A method according to claim [23,] 24
wherein the Colostrinin is non-ovine Colostrinin.

B7
43
44. (AMENDED) The use of Colostrinin in the manufacture of a
medicament for use in the stimulation and/or modulation of the immune
system of [mammals] humans.

B8
45
46. (AMENDED) [Colostrinin for use as a] A prophylactic
medicament for humans[, to prevent or inhibit] comprising Colostrinin for use
in preventing and/or inhibiting the development of Alzheimer's disease.

B9
50
51. (AMENDED) A [nanopeptide] nonapeptide having the
composition and amino acid sequence Val-Glu-Ser-Tyr-Val-Pro-Leu-Phe-Pro
(SEQ ID NO:1) for use as a medicament.

51
52. (AMENDED) [The use of a nanopeptide] A nonapeptide having
the composition and amino acid sequence Val-Glu-Ser-Tyr-Val-Pro-Leu-Phe-

Pro (SEQ ID NO:1) for use in the manufacture of a medicament for treating chronic disorders of the immune system in humans.

B9
53⁵². (AMENDED) The use of a [nanopeptide] nonapeptide having the composition and amino acid sequence Val-Glu-Ser-Tyr-Val-Pro-Leu-Phe-Pro (SEQ ID NO:1) in the manufacture of a medicament for treating chronic disorders of the central nervous system.

54⁵³. (AMENDED) A pharmaceutical composition comprising a [nanopeptide] nonapeptide having the composition Val-Glu-Ser-Tyr-Val-Pro-Leu-Phe-Pro (SEQ ID NO:1) in combination with a physiologically acceptable carrier.

55⁵⁴. (AMENDED) A method of making a pharmaceutical composition comprising combining a [nanopeptide] nonapeptide having the composition and amino acid sequence Val-Glu-Ser-Tyr-Val-Pro-Leu-Phe-Pro (SEQ ID NO:1) with a physiologically acceptable carrier, and forming said mixture into a form in which it can be administered to a patient.
